insights_auto
Why is BH3 up 3,49%?
Dive Deeperchevron_right
BH3:FRA
PTC Therapeutics, Inc.
56,92 €
arrow_upward
+3,49%(+1,92) 1D
12 հոկ, 08:21:59 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BH3...
Open
56,92 €
High
56,92 €
Low
56,92 €
Mkt. cap
5,30 մլրդ
Avg. vol.
0,00
Volume
0,00
52-wk high
77,02 €
52-wk low
52,50 €
No. of employees
991
Open
56,92 €
High
56,92 €
Low
56,92 €
Mkt. cap
5,30 մլրդ
Avg. vol.
0,00
Volume
0,00
52-wk high
77,02 €
52-wk low
52,50 €
No. of employees
991
News stories
From web sources and news partners
Investing.com Canada
·
1 օր առաջ
Form 144 PTC THERAPEUTICS For: 10 October By Investing.com
MarketBeat
·
2 օր առաջ
PTC Therapeutics (NASDAQ:PTCT) Director Sells 2,500 Shares of Company Stock
Investing.com
·
2 օր առաջ
PTC Therapeutics director Michael Schmertzler sells $158k in shares
Investing.com Canada
·
2 օր առաջ
Form 4 PTC Therapeutics Inc For: 9 October By Investing.com
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
Founded01 հնվ, 1998 թ.
HeadquartersWarren, Նյու Ջերսի, Միացյալ Նահանգներ
Sector-
Websiteptcbio.com